Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CPN1 | P15169 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10568595 | 0.98 | GBA1 (0.44) | GBA1KDM1AMAOBCPN1CPB2 | |
| SCHEMBL4782969 | 0.83 | DHODH (0.37) | KDM1AMAOBCPN1CPB2SLC6A3 | |
| SCHEMBL7649264 | 0.82 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3616019 | 0.82 | SLC6A4 (0.48) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4972107 | 0.82 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1862766 | 0.82 | SLC6A4 (0.48) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3616023 | 0.82 | SLC6A4 (0.48) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1862768 | 0.82 | SLC6A4 (0.48) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1862764 | 0.82 | SLC6A4 (0.48) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1866954 | 0.82 | SLC6A4 (0.48) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872028-B2 | Diaminopropanol renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-20100010228-A1 | PROCESS FOR THE ASYMMETRIC REDUCTION OF 3-BENZOYLPIPERIDINES | VITAE PHARMACEUTICALS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100010228-A1 | PROCESS FOR THE ASYMMETRIC REDUCTION OF 3-BENZOYLPIPERIDINES | VITAE PHARMACEUTICALS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090186884-A1 | such as N-(3-amino-2-hydroxypropyl)-3-(1-(2-(2-ethylphenoxy)phenyl)-1-hydroxy-5-;methoxypentyl)piperidine-1-carboxamide, used for the treatment of cardiovascular disorders | VITAE PHARMACEUTICALS, INC. | 2009-07-23 | — | — | US | disclosed |
| WO-2007117557-A2 | DIAMINOPROPANOL RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186884-A1 | such as N-(3-amino-2-hydroxypropyl)-3-(1-(2-(2-ethylphenoxy)phenyl)-1-hydroxy-5-;methoxypentyl)piperidine-1-carboxamide, used for the treatment of cardiovascular disorders | DNPEP, ACE, DPEP1 | GBA1 705/4885KDM1A 1337/4885MAOB 1312/4885 |
| US-20100010228-A1 | PROCESS FOR THE ASYMMETRIC REDUCTION OF 3-BENZOYLPIPERIDINES | QDPR, ADH5, GABARAP | GBA1 1698/4885KDM1A 332/4885MAOB 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.